Trial Profile
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Ibudilast (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms COMBAT-ALS
- Sponsors MediciNova
- 15 Apr 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2026.
- 15 Apr 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 14 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.